Morgan Stanley’s NGM Biopharmaceuticals NGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-155,462
Closed -$247K – 8072
2024
Q1
$247K Sell
155,462
-4,999
-3% -$7.42K ﹤0.01% 5649
2023
Q4
$138K Sell
160,461
-316,779
-66% -$278K ﹤0.01% 5824
2023
Q3
$511K Sell
477,240
-420,892
-47% -$871K ﹤0.01% 5163
2023
Q2
$2.33M Buy
898,132
+41,823
+5% +$149K ﹤0.01% 4322
2023
Q1
$3.49M Buy
856,309
+194,276
+29% +$898K ﹤0.01% 4074
2022
Q4
$3.32M Buy
662,033
+114,974
+21% +$721K ﹤0.01% 4101
2022
Q3
$7.16M Sell
547,059
-44,165
-7% -$669K ﹤0.01% 3322
2022
Q2
$7.58M Buy
591,224
+10,520
+2% +$146K ﹤0.01% 3364
2022
Q1
$8.86M Buy
580,704
+286,737
+98% +$4.47M ﹤0.01% 3049
2021
Q4
$5.21M Buy
293,967
+151,219
+106% +$2.9M ﹤0.01% 3679
2021
Q3
$3M Sell
142,748
-24,027
-14% -$529K ﹤0.01% 4231
2021
Q2
$3.29M Sell
166,775
-75,795
-31% -$1.77M ﹤0.01% 4197
2021
Q1
$7.05M Buy
242,570
+32,287
+15% +$904K ﹤0.01% 3045
2020
Q4
$6.37M Buy
210,283
+57,234
+37% +$1.25M ﹤0.01% 3003
2020
Q3
$2.44M Sell
153,049
-32,472
-18% -$592K ﹤0.01% 3478
2020
Q2
$3.66M Buy
185,521
+182,634
+6,326% +$3.49M ﹤0.01% 2993
2020
Q1
$35K Sell
2,887
-42,864
-94% -$700K ﹤0.01% 5592
2019
Q4
$846K Buy
45,751
+24,029
+111% +$351K ﹤0.01% 4629
2019
Q3
$301K Buy
21,722
+21,697
+86,788% +$326K ﹤0.01% 4930
2019
Q2
$0 Buy
+25
New +$366 ﹤0.01% 6793

Morgan Stanley's NGM Position: Q2 2024 in Review

Morgan Stanley sold out of NGM Biopharmaceuticals (NGM) in Q2 2024, closing a stake of 155,462 shares — an estimated $247K sold.

Morgan Stanley first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $8.86M in Q1 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

  • Morgan Stanley reported no remaining NGM Biopharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Morgan Stanley sold 155,462 NGM Biopharmaceuticals shares in Q2 2024, an estimated $247K.
  • Morgan Stanley first reported a position in NGM Biopharmaceuticals in Q2 2019 and held it in 20 quarters.
  • Morgan Stanley's NGM Biopharmaceuticals position peaked at $8.86M in Q1 2022.
  • 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals as of Q2 2024.

Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.